The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.
For more than 60 years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.
Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.
Careers
We look for the best and brightest of tomorrow and develop careers from the ground up.
News and Featured Insights
Leading Matters
Client Highlights
California Supreme Court Expands Access to Electronic Court Recording in Wilson Sonsini Litigation
On August 10, 2026, the California Supreme Court issued a unanimous opinion in Family Violence Appellate Project v. Superior Court, No. S288176, expanding access to electronic recording of trial court hearings when no court reporter is available. The court’s opinion recognized that a verbatim record of court proceedings can be essential to access to justice and that electronic recording represents an effective technology for meeting that need, particularly for indigent parties who cannot afford to hire a court reporter. The decision further expands upon access to electronic recording provided in general orders enacted by trial courts around the state.
Client Highlights
Wilson Sonsini Advises Cylinder Health on $105 Million Acquisition by Hinge Health
On August 4, 2026, Hinge Health, a digital healthcare company, announced that it has signed a definitive agreement to acquire Cylinder Health, a leader in virtual-first digestive healthcare, for $105 million in cash consideration. Wilson Sonsini Goodrich & Rosati advised Cylinder Health on the transaction.
Client Highlights
Firm Advises Braveheart Bio on Patent Matters Related to $382.5 Million IPO
On August 5, 2026, Braveheart Bio, a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, announced the pricing of its upsized initial public offering of 21,250,000 shares of its common stock at a public offering price of $18.00 per share. The gross proceeds from the initial public offering, before deducting underwriting discounts and commissions and other offering expenses payable by Braveheart Bio, are expected to be $382.5 million, excluding any exercise of the underwriters’ option to purchase additional shares of common stock. Wilson Sonsini Goodrich & Rosati advised Braveheart Bio on patent matters related to the transaction.
Client Highlights
Firm Advises Expedition Therapeutics on Patent Matters Related to $115 Million Series B
On August 5, 2026, Expedition Therapeutics, a clinical-stage biotechnology company developing novel oral small molecule therapies for inflammatory and respiratory diseases, announced the closing of an oversubscribed $115 million Series B financing led by General Atlantic, a leading global investor, with participation from RA Capital and Vivo Capital and existing investors Sofinnova Investments, Novo Holdings, Forbion, Dawn Biopharma (a platform controlled by KKR), Adage Capital Management, Balyasny Asset Management, Logos Capital, Sanofi Ventures, BVF Partners, and Venrock Healthcare Capital Partners. Wilson Sonsini Goodrich & Rosati is patent counsel to Expedition and advises the company on all patent matters, including those related to this transaction.
Client Highlights
Wilson Sonsini Advises Flagler Health on $50 Million Series B
On August 11, 2026, Flagler Health, which provides AI-native practice management software currently focused on musculoskeletal (MSK) care, announced the completion of a $50 million Series B funding round. Bessemer Venture Partners led the financing joined by SignalFire, Alumni Ventures, Streamlined, 186 Ventures, Proof VC, Tribeca Ventures, and Offscript. The new funding accelerates the company’s expansion across every MSK practice in the U.S. Wilson Sonsini Goodrich & Rosati advised Flagler Health on the transaction.
Client Highlights
Wilson Sonsini Advises Hadrian on $1.37 Billion Series D
On August 6, 2026, Hadrian, the advanced manufacturing company building highly automated factories for America, announced $1.37 billion in new equity financing to accelerate the buildout of the domestic manufacturing capacity needed to deliver America's most critical defense, aerospace, and industrial systems. The raise values Hadrian at $7.87 billion. Wilson Sonsini Goodrich & Rosati advised Hadrian on the transaction.
The financing will be co-led by WCM Investment Management, Washington Harbour Partners, Valor Equity Partners, 137 Ventures, and Baillie Gifford. JPMorganChase's Strategic Investment Group joined as anchor co-lead, investing through the firm's Security and Resiliency Initiative. The round also included major participation by 1789 Capital, as well as Morgan Stanley Wealth Management, funds managed by Apollo, accounts advised by T. Rowe Price Associates, Inc., CapitalG, Andreessen Horowitz, Founders Fund, Lux Capital, Altimeter, Construct Capital, and existing investors.
The Wilson Sonsini team that advised Hadrian on the transaction was led by partners Rezwan Pavri and Colin Conklin. The team also included:
Corporate
Jackie Jung
Andrew Lu
Nara Jo
Mary Cruz
The financing will be co-led by WCM Investment Management, Washington Harbour Partners, Valor Equity Partners, 137 Ventures, and Baillie Gifford. JPMorganChase's Strategic Investment Group joined as anchor co-lead, investing through the firm's Security and Resiliency Initiative. The round also included major participation by 1789 Capital, as well as Morgan Stanley Wealth Management, funds managed by Apollo, accounts advised by T. Rowe Price Associates, Inc., CapitalG, Andreessen Horowitz, Founders Fund, Lux Capital, Altimeter, Construct Capital, and existing investors.
The Wilson Sonsini team that advised Hadrian on the transaction was led by partners Rezwan Pavri and Colin Conklin. The team also included:
Corporate
Jackie Jung
Andrew Lu
Nara Jo
Mary Cruz
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025.